EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Monitoring SARS-CoV-2 genetic variability: A post-market surveillance workflow for combined bioinformatic and laboratory evaluation of commercial RT-PCR assay performance

Barbara Kosińska-Selbi iD, Justyna Kowalczyk, Jagoda Pierscińska iD, Jarosław Wełeszczuk, Luis Peñarrubia, Benjamin Turner, Josep Pareja iD, Roberto Porco, Rubi Diaz-Hernandez, Martí Juanola-Falgarona, Melisa Rey, Davide Manissero und 1 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0294271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Barbara Kosińska-Selbi und 12 weiteren Autor:innen. Beteiligte Einrichtung: QIAGEN Wrocław Sp. z o.o., Wrocław, Poland. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: QIAGEN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The speed at which Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is mutating has made it necessary to frequently assess how these genomic changes impact the performance of diagnostic real-time polymerase chain reaction (RT-PCR) assays. Herein, we describe a generic three-step workflow to assess the effect of genomic mutations on inclusivity and sensitivity of RT-PCR assays.

Methods

Sequences collected from the Global Initiative on Sharing All Influenza Data (GISAID) were mapped to a SARS-CoV-2 reference genome to evaluate the position and prevalence of mismatches in the oligonucleotide-binding sites of the QIAstat-Dx, an RT-PCR panel designed to detect SARS-CoV-2. The frequency of mutations and their impact on melting temperature were assessed, and sequences flagged by risk-based criteria were examined in vitro .

Results

Out of 8,900,393 SARS-CoV-2 genome sequences analyzed, only 173 (0.0019%) genomes contained potentially critical mutations for the QIAstat-Dx; follow-up in-vitro testing confirmed no impact on the assays’ performance.

Conclusions

The current study demonstrates that SARS-CoV-2 genetic variants do not affect the performance of the QIAstat-Dx device. It is recommended that manufacturers incorporate this workflow into obligatory post-marketing surveillance activities, as this approach could potentially enhance genetic monitoring of their product.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansReverse Transcriptase Polymerase Chain ReactionWorkflowComputational BiologySensitivity and SpecificityCOVID-19 Testing

Autor:innen und Institutionen

  • QIAGEN Wrocław Sp. z o.o., Wrocław, Poland.
  • QIAGEN (Previously STAT-Dx Life S.L.), Barcelona, Spain.
  • QIAGEN Digital Insights, Aarhus, Denmark.
  • QIAGEN Manchester Ltd, CityLabs, Manchester, United Kingdom.

ORCID-Profile: Barbara Kosińska-Selbi, Jagoda Pierscińska, Josep Pareja, Anna Blacha

Förderung

  • QIAGEN

Zitieren

APA

Kosińska-Selbi, B., Kowalczyk, J., Pierscińska, J., Wełeszczuk, J., Peñarrubia, L., Turner, B., Pareja, J., Porco, R., Diaz-Hernandez, R., Juanola-Falgarona, M., Rey, M., Manissero, D., & Blacha, A. (2024). Monitoring SARS-CoV-2 genetic variability: A post-market surveillance workflow for combined bioinformatic and laboratory evaluation of commercial RT-PCR assay performance. PLOS ONE. https://doi.org/10.1371/journal.pone.0294271

Vancouver

Kosińska-Selbi B, Kowalczyk J, Pierscińska J, Wełeszczuk J, Peñarrubia L, Turner B, et al. Monitoring SARS-CoV-2 genetic variability: A post-market surveillance workflow for combined bioinformatic and laboratory evaluation of commercial RT-PCR assay performance. PLOS ONE. 2024. doi:10.1371/journal.pone.0294271

BibTeX
@article{KosiskaSelbi2024,
  author = {Kosińska-Selbi, Barbara and Kowalczyk, Justyna and Pierscińska, Jagoda and Wełeszczuk, Jarosław and Peñarrubia, Luis and Turner, Benjamin and Pareja, Josep and Porco, Roberto and Diaz-Hernandez, Rubi and Juanola-Falgarona, Martí and Rey, Melisa and Manissero, Davide and Blacha, Anna},
  title = {Monitoring SARS-CoV-2 genetic variability: A post-market surveillance workflow for combined bioinformatic and laboratory evaluation of commercial RT-PCR assay performance},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0294271}
}
Kostenlos starten →